Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

In 1997 an international group of scientists organized a meeting in Barcelona, Spain, to discuss the use of biomarkers in the management of patients with bladder cancer. This meeting was the offspring of an - initially informal - group that finally resulted in the foundation and incorporation of the International Bladder Cancer Network (IBCN) e.V. in 2005. Over the years the group has supported several research initiatives and generated several recommendations on the use of biomarkers in the diagnosis and treatment of bladder cancer. Meeting quality was generated by inviting experts presenting state-of-the-art lectures or work in progress reports, interdisciplinarity and the limited number of participants supporting an open and personal exchange resulted in a format increasingly attracting participants from all over the world. The recent limitations caused by the Covid-19 pandemic were partially met by organizing several well attended webinars. The future challenge is to maintain the IBCN meeting spirit despite an increasing interest of the scientific community and industrial partners to participate. However, the integration of and interaction between increasingly more specialized disciplines is a challenge that can be better catalyzed by an international multidisciplinary network than mostly national professional associations. Copyright © 2022. Published by Elsevier Inc.


Lars Dyrskjøt, Antonia Vlahou, Peter C Black, Michael Droller, H Barton Grossmann, Peter J Goebell, Ashish M Kamat, Roman Nawroth, Roland Seiler, Tilman Todenhöfer, Stephen B Williams, Bernd J Schmitz-Dräger. 25 years International Bladder Cancer Network (IBCN): The past, the present, and the future. Urologic oncology. 2023 Jul;41(7):302-306

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 36437158

View Full Text